AstraZeneca announced an eight-program collaboration with China’s CSPC Pharmaceuticals to acquire rights to a once-monthly injectable weight-management pipeline. The agreement grants AZN exclusive global rights outside Greater China for eight preclinical and early-stage obesity assets, positioning the company to expand its cardiovascular, renal and metabolism portfolio with differentiated therapies designed to provide sustained efficacy and improved patient convenience.

Under the terms of the deal, AstraZeneca will pay CSPC $1.2 billion upfront. The partnership also includes up to $17.3 billion in research, regulatory and commercial milestones, tied to first-in-class designations, clinical trial success and cumulative global sales thresholds. AZN will fund all future development, regulatory filings and commercialization efforts, reflecting its confidence in achieving peak annual revenues well above industry benchmarks for obesity treatments.

This collaboration aligns with AstraZeneca’s 2030 ambition to reach $80 billion in annual revenue and launch 20 new medicines. The transaction leverages AZN’s global commercial infrastructure—covering more than 125 countries—and underscores its focus on high-growth Cardiovascular, Renal & Metabolism franchises. By augmenting its pipeline with monthly injectable candidates, AstraZeneca strengthens its position against competitors and addresses a major unmet need in chronic disease management, potentially adding several billion dollars to its mid-term revenue mix.

On the same week, AstraZeneca began trading ordinary shares directly on the New York Stock Exchange, aligning listings on NYSE, the London Stock Exchange and Nasdaq Stockholm. The move ended its American Depositary Receipt program on Nasdaq, while maintaining inclusion in the FTSE 100 and OMX Stockholm 30. AZN’s harmonized global listing is expected to broaden its U.S. investor base and support funding for late-stage pipeline investments, including the newly acquired CSPC obesity programs.